Agilent acquired Luxcel Biosciences

January 10, 2018 | Wednesday | News

Focused R&D expansion providing core competencies in biosensor chemistries and bioassay solutions targeting pharma/biopharma applications for near and long-term portfolio expansion

Agilent Technologies Inc. announced that it has acquired Cork, Ireland-based Luxcel Biosciences (“Luxcel”), a developer of real time fluorescence plate-reader based in vitro cell assay kits.

This acquisition expands Agilent’s cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.

Luxcel is developing a portfolio of in vitro cell-based assay kits and solutions targeting cell metabolism, drug safety and toxicity, as well as hypoxia and oxidative stress for a variety of life science customers from research institutions to pharmaceutical companies.

Scientists use this technology to understand the roll of cell metabolism across a variety of important research areas including cancer, metabolic disorders, cardiovascular disease, immunology, and infectious disease. 

Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in providing specialized instruments and live-cell, kinetic assays. 

The Luxcel team will remain in Cork and form a dedicated sensor chemistries and bioassay solutions group within Agilent’s Cell Analysis Division.

Financial terms of the deal are not being disclosed.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy